CAJ | 학술논문

目的：探讨Ⅲ型β?微管蛋白（ TUBB3）和微管相关蛋白tau（ MAPT）在非小细胞肺癌（ NSCLC）组织中的表达水平及其对紫杉类化疗药物敏感性的预测价值。方法收集55例未经化疗的不能手术的转移性或复发晚期NSCLC患者的肿瘤组织标本，一线治疗均采用铂类联合紫杉类双药化疗方案，2个周期后评估疗效，将完全缓解和部分缓解的患者归为敏感组，疾病稳定的患者归为次敏感组，疾病进展的患者归为耐药组。采用逆转录?聚合酶链反应检测3组TUBB3和MAPT的mRNA水平，分析NSCLC组织中TUBB3和MAPT mRNA的相关性，采用免疫组织化学法检测3组TUBB3和MAPT的蛋白表达情况。结果在55例NSCLC组织中，TUBB3和MAPT mRNA在3组均有不同程度的表达，且两者蛋白均定位在细胞质内。敏感组、次敏感组及耐药组的TUBB3 mRNA水平分别为0?12±0?13、0?17±0?24和0?51±0?19，MAPT mRNA水平分别为0?09±0?05、0?14±0?09和0?46±0?21，TUBB3阳性表达率分别为22?22％（4／18）、20?00％（5／20）和70?59％（12／17），MAPT阳性表达率分别为16?67％（3／18）、25?00％（4／20）和52?94％（9／17）；耐药组的TUBB3和MAPT mRNA水平及阳性率均高于其余两组（P＜0?05），且敏感组和次敏感组的以上差异均无统计学意义（P＞0?05）。 TUBB3和 MAPT的 mRNA水平呈正相关（r＝0?219，P＝0?047）。结论 TUBB3和MAPT的mRNA和蛋白表达与紫杉类药物的敏感性有关，高表达者提示对紫杉类药物耐药，联合检测TUBB3和MAPT可能对紫杉类药物化疗敏感性具有较好的预测价值。
목적：탐토Ⅲ형β?미관단백（ TUBB3）화미관상관단백tau（ MAPT）재비소세포폐암（ NSCLC）조직중적표체수평급기대자삼류화료약물민감성적예측개치。방법수집55례미경화료적불능수술적전이성혹복발만기NSCLC환자적종류조직표본，일선치료균채용박류연합자삼류쌍약화료방안，2개주기후평고료효，장완전완해화부분완해적환자귀위민감조，질병은정적환자귀위차민감조，질병진전적환자귀위내약조。채용역전록?취합매련반응검측3조TUBB3화MAPT적mRNA수평，분석NSCLC조직중TUBB3화MAPT mRNA적상관성，채용면역조직화학법검측3조TUBB3화MAPT적단백표체정황。결과재55례NSCLC조직중，TUBB3화MAPT mRNA재3조균유불동정도적표체，차량자단백균정위재세포질내。민감조、차민감조급내약조적TUBB3 mRNA수평분별위0?12±0?13、0?17±0?24화0?51±0?19，MAPT mRNA수평분별위0?09±0?05、0?14±0?09화0?46±0?21，TUBB3양성표체솔분별위22?22％（4／18）、20?00％（5／20）화70?59％（12／17），MAPT양성표체솔분별위16?67％（3／18）、25?00％（4／20）화52?94％（9／17）；내약조적TUBB3화MAPT mRNA수평급양성솔균고우기여량조（P＜0?05），차민감조화차민감조적이상차이균무통계학의의（P＞0?05）。 TUBB3화 MAPT적 mRNA수평정정상관（r＝0?219，P＝0?047）。결론 TUBB3화MAPT적mRNA화단백표체여자삼류약물적민감성유관，고표체자제시대자삼류약물내약，연합검측TUBB3화MAPT가능대자삼류약물화료민감성구유교호적예측개치。
Objective To explore the expressions of class Ⅲ β?tubulin ( TUBB3 ) and microtubule associated protein?tau ( MAPT) in tumor tissue of patients with non?small cell lung cancer( NSCLC) , and to evaluate the value of TUBB3 and MAPT in pre?dicting the chemosensitivity of taxanes. Methods The tumor tissue specimens from 55 patients with chemo?naive and unoperable meta?static or recurrent NSCLC were collected. All patients received platinum?taxanes chemotherapy as the first?line therapy. According to the efficacy assessed after two cycles, 55 patients were divided into 3 groups. Patients with complete remission or partial remission were classed as sensitive group, and patients with stable disease were less sensitive group, and patients with progressive disease were resist?ance group. Reverse transcription polymerase chain reaction was used to measure the mRNA levels of TUBB3 and MAPT, and the cor?relation between mRNA expression of TUBB3 and MAPT were analyzed. The immunohistochemistry was used to detect the protein ex?pression levels of TUBB3 and MAPT. Results Expression of TUBB3 and MAPT mRNA in 55 cases of NSCLC tissues were obesrved in varying degrees. TUBB3 and MAPT protein were located in cytoplasm. In sensitive group, less sensitive group and resistance group, the levels of TUBB3 mRNA were 0?12±0?13, 0?17±0?24 and 0?51±0?19 and the levels of MAPT mRNA were 0?09±0?05, 0?14±0?09 and 0?46±0?21, respectively. The positive expression rates of TUBB3 and MAPT were 22?22%(4/18) and 16?67%(3/18) in sensi? <br> tive group, 20?00%(5/20) and 25?00%(4/20) in less sensitive group, and 70?59%(12/17) and 52?94%(9/17) in resistance group. The mRNA levels and positive expression rates of both TUBB3 and MAPT were higher in resistance group versus other two groups(P<0?05). No significant difference were observed on the above indices between sensitive group and less sensitive group(P>0?05). There was a positive correlation between the mRNA expression of TUBB3 and MAPT(r=0?219, P=0?047). Conclusion The expression of TUBB3 and MAPT might predict the chemosensitivity of taxanes in patients with NSCLC. Patients with high expres?sion of TUBB3 and MAPT might show resistance to taxanes. Combined detection of TUBB3 and MAPT might be more valuable in pre?dicting chemosensitivity to taxanes.